Drug Profile
Nelipepimut S companion diagnostic - Sellas Life Sciences Group/Leica
Alternative Names: E75 companion diagnostic - Sellas Life Sciences Group/Leica; NueVax™ companion diagnostic - Sellas Life Sciences Group/LeicaLatest Information Update: 20 Feb 2019
Price :
$50
*
At a glance
- Originator Galena Biopharma; Leica Biosystems
- Developer Leica Biosystems; Sellas Life Sciences Group
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 20 Feb 2019 No recent reports of development identified for Phase-III for Breast cancer (Diagnosis) in USA, Canada, Israel, Europe (unspecified route)
- 29 Dec 2017 Galena Biopharma merged with Sellas Life Sciences and subsequently changed its name to Sellas Life Sciences Group
- 05 Jun 2015 Phase-III development is ongoing in USA, Canada and Europe